Insulin degludec/insulin aspart

Drug Profile

Insulin degludec/insulin aspart

Alternative Names: DegludecPlus; IDegAsp; IDegAsp 15; Insulin aspart/insulin degludec; Insulin aspart/NN1250; Insulin Degludec/Insulin Aspart 15; NN1045; NN1250/insulin aspart; NN5401; Ryzodeg; SIAC; Soluble insulin analogue combination

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Sep 2016 Novo Nordisk completes a phase I pharmacokinetics trial in Healthy volunteers in China (SC) (NCT02844790)
  • 01 Sep 2016 Phase-III clinical trials in Type-2 diabetes mellitus in Serbia (SC) (NCT02906917)
  • 01 Sep 2016 Novo Nordisk initiates enrolment in a phase-III trial in Type-2 diabetes mellitus in Turkey, Russia, Czech Republic, Algeria, India, USA (SC) (NCT02906917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top